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Accumulation of amyloid beta peptides is thought to initiate the pathogenesis of Alzheimer’s disease. However, the precise mecha-
nisms mediating their neurotoxicity are unclear. Our microarray analyses show that, in Drosophila models of amyloid beta 42 tox-
icity, genes involved in the unfolded protein response and metabolic processes are upregulated in brain. Comparison with the brain
transcriptome of early-stage Alzheimer’s patients revealed a common transcriptional signature, but with generally opposing directions
of gene expression changes between flies and humans. Among these differentially regulated genes, lactate dehydrogenase (Ldh) was
up-regulated by the greatest degree in amyloid beta 42 flies and the human orthologues (LDHA and LDHB) were down-regulated in
patients. Functional analyses revealed that either over-expression or inhibition of Ldh by RNA interference (RNAi) slightly exacer-
bated climbing defects in both healthy and amyloid beta 42-induced Drosophila. This suggests that metabolic responses to lactate de-
hydrogenase must be finely-tuned, and that its observed upregulation following amyloid beta 42 production could potentially repre-
sent a compensatory protection to maintain pathway homeostasis in this model, with further manipulation leading to detrimental
effects. The increased Ldh expression in amyloid beta 42 flies was regulated partially by unfolded protein response signalling, as
ATF4 RNAi diminished the transcriptional response and enhanced amyloid beta 42-induced climbing phenotypes. Further functional
studies are required to determine whether Ldh upregulation provides compensatory neuroprotection against amyloid beta 42-induced
loss of activating transcription factor 4 activity and endoplasmatic reticulum stress. Our study thus reveals dysregulation of lactate de-
hydrogenase signalling in Drosophila models and patients with Alzheimer’s disease, which may lead to a detrimental loss of metabolic
homeostasis. Importantly, we observed that down-regulation of ATF4-dependent endoplasmic reticulum-stress signalling in this con-
text appears to prevent Ldh compensation and to exacerbate amyloid beta 42-dependent neuronal toxicity. Our findings, therefore,
suggest caution in the use of therapeutic strategies focussed on down-regulation of this pathway for the treatment of Alzheimer’s dis-
ease, since its natural response to the toxic peptide may induce beneficial neuroprotective effects.
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Introduction
Alzheimer’s disease is the most common form of dementia,
and affects over 50 million people worldwide.1 The main risk
factor for Alzheimer’s disease is advancing age,2 with inci-
dence increasing from 0.6% at age 60–65 to over 8% for
people aged over 85.3 Although the age-specific incidence of
Alzheimer’s disease has declined in many parts of the world
in recent years,4 human lifespan has increased steadily over
the last decades.5 Alzheimer’s disease is therefore becoming
one of the most common causes of disability and death, with
no effective preventative measures or cures yet available.
Alzheimer’s disease is characterized by widespread neu-
rodegeneration, but how this is mediated is still unclear.
Pathologically, brains of Alzheimer’s disease patients dis-
play an intracellular accumulation of neurofibrillary tan-
gles, composed of Tau protein, and a substantial increase
in extracellular amyloid plaques composed of amyloid
beta (Aß) peptides, derived from the mis-processing of
the amyloid precursor protein (APP). The most widely
accepted model of Alzheimer’s disease aetiology is the
amyloid hypothesis, first postulated in 1992,6 and based
on the observation that all early onset, dominantly inher-
ited forms of the disease are caused by mutations that
lead to the abnormal-processing of APP. The amyloid hy-
pothesis states that Alzheimer’s disease is initiated by the
accumulation of toxic Aß peptides,6 which induce a
downstream cascade of events, ultimately resulting in
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neuronal cell death. Yet, the mechanisms by which Aß
accumulation leads to neuronal dysfunction remain to be
resolved.
Efforts to identify pathways leading to neuronal cell death
have been driven forward by recent advances in single-cell
sequencing. This has facilitated the identification of cell-type-
specific responses to accumulation of toxic entities and formu-
lation of a more precise picture of the cellular phase of
Alzheimer’s disease pathogenesis,7 during which specific neur-
onal responses to the accumulation of toxic proteins ultimately
lead to the demise of several neuronal populations. A recent
study using single-cell sequencing of Alzheimer’s disease patient
brains has shown that different cell types show distinct and
sometimes opposing transcriptional responses to disease.8
Whether these transcriptional events play a causal role in dis-
ease progression, or whether they reflect bystander responses
to proteotoxicity, requires further study.
Model organisms play a key role in investigations where
genes highlighted by human studies can be manipulated to de-
termine whether they affect disease development.9 Drosophila
models are excellent for uncovering the molecular mechanisms
of disease, thanks to their powerful genetic toolkit developed
during the century that flies have been used in research.10
Moreover, 75% of human disease genes have homologues in
flies.11 Additionally, their short lifespan enables the assessment
of pathological responses to toxic insults across the lifespan of
a complex organism. Drosophila Aß toxicity models are wide-
ly used in neurodegeneration research 12 and display a range
of pathologies, including neuronal dysfunction, behavioural de-
cline and early death in response to amyloid accumulation in
the fly brain. We have used an inducible model to express
pathogenic Arctic Aß42, tagged with an endoplasmic reticu-
lum (ER) export signal peptide,13 specifically in neurons of
the adult fly, thereby removing any confounding developmen-
tal effects. These flies show shortened lifespan, climbing defects
and neurodegeneration phenotypes.14
Fly models have shown cellular responses to Aß accumula-
tion similar to those seen in Alzheimer’s disease patients. For
example, the ER stress response is induced in fly models of
Aß toxicity15 and in human Alzheimer’s disease brain.16,17
Functional genomic approaches using Drosophila have con-
firmed that this is a protective response, since up-regulation of
specific components of the Unfolded Protein Response (UPR),
including Xbp1 and BiP,15,18 can protect against Aß toxicity.
Similarly, Nrf2, a transcriptional activator of cell protection
genes, has been shown to be altered in Alzheimer’s disease
patients,19 with some studies finding up-regulation and others
down-regulation, possibly due to looking at different disease
stages. Our studies in flies have shown that restoring Nrf2 ac-
tivity can ameliorate Aß toxicity by promoting degradation of
the amyloid peptide and increasing resistance to cellular
stress.20 Therefore, Drosophila appear to mount an evolution-
arily conserved response to Aß accumulation in the brain
and, due to the ease of genetic manipulation, flies present a
powerful tool to identify molecular mediators of Alzheimer’s
disease pathogenesis and thus potential targets for drug devel-
opment and clinical translation.
We set out to identify potential age-specific responses to
Aß accumulation in the Drosophila brain and to identify
conserved transcriptional responses to amyloid toxicity be-
tween fly and human AD. Given that Alzheimer’s disease is
a late-onset disorder, we monitored transcriptional responses
at different ages. However, the majority of transcriptional
alterations in response to Aß42 in older fly brains over-
lapped with those in young flies, suggesting that these repre-
sent general brain-specific responses to amyloid early in
disease pathogenesis. Comparing microarray analysis of fly
brains to single-cell transcriptomics of brains of Alzheimer’s
disease patients, we identified several genes that are differen-
tially expressed, although reciprocally regulated, in flies and
humans, including genes implicated in metabolism, ER-stress,
proteostasis and cell cycle. We further identified Ldh as a
conserved gene mis-expressed in the presence of Aß down-
stream of ATF4-dependent UPR activation. Activation of the
UPR could potentially modulate a protective metabolic re-
sponse in Alzheimer’s disease that warrants further investiga-
tion for potential therapeutic benefit.
Materials and methods
Drosophila microarray analyses
Upstream Activating Sequence UAS-ArcAß42/þ; elavGS/þ
flies were treated, for 7days, with standard SY medium con-
taining 200mM Mifepristone (RU486) or medium containing
carrier alone (RU) from either 5 or 20days of age and
brains dissected one week after withdrawal of induction, at
19 or 34days of age, respectively. Treatments for each repli-
cate were staggered and brains dissected on consecutive days
over a 2-hour period to circumvent circadian effects. Frozen
fly heads from each replicate were used to measure Aß42
peptide concentrations by enzyme-linked immunosorbent assay
(ELISA).
Brain tissues used for microarray analyses were stored in
Allprotect tissue reagent (Qiagen # 76405) at 80C and,
for each array, RNA extracted from 25 brains using RLT
buffer þ 0.01% b-mercaptoethanol and purified with
RNeasy columns (Qiagen, Valencia, CA, USA) following
the manufacturer’s instructions. The quality and concentra-
tion of RNA was confirmed using an Agilent Bioanalyzer
2100 (Agilent Technologies, Santa Clara, CA, USA), and
further procedures followed the standard Affymetrix proto-
col. All samples were hybridized to the Drosophila
Genome 2.0 Genechip. In total, 5 biological replicates of
each condition (RU 19d, þRU [d 5–12] 19d, RU 34d
and þRU [d 20–27] 34d) were performed.
Differential expression analysis of Drosophila brain
data-sets
Differential gene expression was determined as previously
described.20 Briefly, raw data (cel files) were processed to
correct for probe-sequence biases using gcrma (http://www.
bioconductor.org) in R (http://www.r-project.org) and
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presence of target transcripts, with a P-value <0.111,
determined using Affymetrix’s MicroArray Suite 5.0 (bio-
conductor’s package affy).21 Raw data were summarized
and normalized using the Robust Multichip Average (rma)
function (bioconductor’s package affy22). A linear model
was fitted and differential expression of genes was assessed
using the empirical Bayes moderated t-statistic in R’s
limma package.23 P-values were adjusted for multiple hy-
pothesis testing by applying the Benjamini and Hochberg
correction for false discovery rate. Summarized probe-sets
were mapped to transcripts using R’s package ‘drosophi-
la2.db’. Transcripts not mapping to any known or pre-
dicted genes were excluded from further analysis.
Gene ontology analysis of Drosophila brain data-sets
Pathway analyses were performed as previously described.20
The Wilcoxon rank sum test, as implemented in Catmap,24
was used to determine significant enrichment of Gene
Ontology (GO) categories. FlyBase (http://flybase.org) gene
identifiers were mapped to Gene Ontology identifiers
(FlyBase version FB2014_01). Ranks of genes were based on
the P-value derived from the Bayes t-statistic for differential
expression. To account for multiple hypothesis testing, an en-
richment of GO terms was deemed statistically significant if
the P-value derived from the Wilcoxon rank sum test was
1.0  1005. Gene lists were sorted by log-fold change
and P-value. For all microarray experiments, two sets of lists
were derived; a gene list comprising most differentially up-
regulated (log-fold change > 0) genes at the top of the list
and most differentially down-regulated genes (log-fold change
< 0) at the bottom of the list (termed up-to-down) and vice
versa (termed down-to-up). If a GO category was found to
be statistically significant in the up-to-down list, this GO was
referred to as up-regulated, and conversely if statistically sig-
nificant in the down-to-up list, this GO was referred to as
down-regulated, meaning that a large enough proportion of
genes in these categories were found to be up or down-regu-
lated respectively. Statistical significance of overlaps of GOs
between age-groups was determined using Fisher’s exact test.
To account for multiple hypothesis testing, a P-value cut-off
of 1.0  1005 was used.
Comparison of human Alzheimer’s disease
single-cell transcriptional changes versus Drosophila
models
Human genes differentially expressed between early and no
Alzheimer pathology in six cell types were obtained from
Supplementary Table 2 of Mathys et al. Human genes were
considered significant according to the author’s definition
(column ‘DEGs.Ind.Model’). Fly genes were defined as differ-
entially expressed if their adjusted P-value was <0.05. To
analyse sharing in candidate genes between Drosophila and
humans, we first transformed human candidate genes to fly
orthologues using a table with human to Drosophila ortho-
logue mappings from the Alliance of Genome Resources
(AIG) (Alliance of Genome Resources), which employs the
Drosophila RNAi Screening Center Integrative Ortholog
Prediction Tool. Only genes for which the forward (human
to fly orthologues) and reverse orthologue search (fly ortho-
logues to human genes) resulted in the same top gene hits
were included (i.e. columns ‘BestForward’ and ‘BestReverse’
were filtered for ‘yes’). We included all matching orthologue
hits when one human gene mapped to multiple fly ortho-
logues. Where different human genes mapped to the same
fly orthologue, the orthologue hit was only considered once.
Genes that were not in common between the above
Drosophila brain and human single-cell datasets were
removed from the analysis, so that the background size var-
ied between 4,464 and 5,757 genes dependent on the human
cell type. Shared candidate genes between the Drosophila
and human cell type datasets were then obtained and
SuperExactTest (Wang et al.) used to assess whether the
number of overlapping genes is significantly different than
expected by chance. Performing the analysis based on human
genes resulted in qualitatively similar results (not shown).
Fly husbandry and stocks
All flies were reared at 25C on a 12-h:12-h light:dark cycle
at constant humidity and on standard sugar-yeast-agar (SYA)
medium (agar, 15g/l; sugar, 50g/l; autolyzed yeast, 100g/l;
nipagin, 30ml/l (of 10% solution in ethanol) and propionic
acid, 2ml/l). For induction with RU486, 24–48h after eclo-
sion, the female flies carrying a heterozygous copy of elavGS
and at least one UAS construct were fed SYA medium supple-
mented with 200mM mifepristone (RU486) to induce trans-
gene expression. ElavGS, derived from the original elavGS
301.2 line25 was a gift from Dr H. Tricoire (CNRS), the
UAS-Aß42Arc stock was a gift from Dr D. Crowther
(University of Cambridge). The UAS-Ldh stock was generated
by PCR amplifying the genomic locus with primers (ATGGCC
GCCATTAAGGACAGTCTGTTGGC and TTAGAACTTC
AGACCAGCCTGGACATCGGA), and gateway cloned into an
entry vector and transferred into a gateway compatible
pUASTattB vector according to standard protocols and
inserted into the attP40 locus. LdhRNAi stock: y1 v1;
PfTRiP.HMS00039gattP2, PflacWgsimaj11B7 and ATF4
RNAi stock, PfTRiP.JF02007gattP2 were all from
Bloomington stock centre. All flies were back-crossed six
times into a w1118 (for over-expression lines) or a v1wþ
background (for RNAi lines) line to ensure homogenous
back-ground.
Lifespan analysis
Flies were raised at a uniform density in 200 ml bottles.
After eclosion, flies were allowed to mate for 24–48 h. At
least 110–150 females of the appropriate genotype were
split into groups of 15 and housed in vials containing
SYA medium and either carrier alone or RU486. Deaths
were scored and flies tipped onto fresh food three times
a week. All lifespans were performed at 25C.
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Climbing assay
The climbing assays for Aß expressing flies were performed
as previously described.14 Briefly, 15 flies were placed in a
25cm pipette, tapped to the bottom, and allowed to climb
for 45s. The number of flies in the top 5 cm, centre, and
bottom 3 cm was scored. A performance index was calcu-
lated for each time point and plotted. For flies expressing
Ldh and LdhRNAi in neurons climbing assays were per-
formed according to Woodling et al.26 Briefly, flies allowed
to climb in a vertical 20cm column formed by two plastic
vials, each fly height was scored in ImageJ and used for stat-
istical analysis. Climbing assays were performed every 3–
4 days and at least 100 flies were used per condition.
Quantitative PCR
Total RNA was extracted from 15 to 20 fly heads using
Trizol (Invitrogen) and subsequently treated with DNAse
I (Ambion) for DNA digestion. The RNA was then re-
verse transcribed using Superscript II (Invitrogen) with
oligo(dT) primers. Quantitative gene expression analysis
was performed on a 7900HT real-time PCR system
(Applied Biosystems) using SYBR-green technology (ABI).
Relative quantities of transcripts were determined using
the relative standard curve method normalized to eIF.
Primer sequences can be found in Table 1.
LDH assay
To measure LDH activity, 10 fly heads were homogenized
in 62.5ml of 0.2 M NaPO4, pH 6.5 plus 0.2% phenyl-
thiourea. The samples were centrifuged at 21,000 g for 5 min
at 4C, the clear supernatant was taken to measure the ac-
tivity of LDH. Protein extracts were quantified using the
Bradford protein assay (Bio-Rad protein assay reagent; Bio-
Rad laboratories Ltd (UK)). For the measurement in the dir-
ection pyruvate to lactate, the assay mixture contained
0.05M sodium phosphate, pH 6.5, 1 mM sodium pyruvate,
and 0.2mM NADH. For the measurement in the direction
lactate to pyruvate, the assay mixture contained 0.1M so-
dium phosphate, pH 7.5, 100 mM D, L-lithium lactate, and
4.13mM NADþ. Blank samples contained everything but
NADH or NADþ. 10mg of the protein extracts were added
to the reaction mixture. The activity of LDH was measured
spectrophotometrically at 25C at 340nm on a Tecan
Infinite M200 platereader. The LDH activity is represented
as a slope of the reaction.
Lactate pyruvate levels
To measure lactate and pyruvate levels, 15 fly heads were
homogenized in 30ml 4% cold Trichloroacetic acid. The
samples were centrifuged for 15min at 11,500g for 15 min
at 4C. 20ml of the clear supernatant was neutralized with
180ml of 1:10 dilution of 1M Tris-HCL pH8. Lactate and
pyruvate levels were measured using the Lactate assay kit
(Sigma) and the Pyruvate assay kit (Sigma). The samples
were diluted 1:10 in the assay buffer, then the pyruvate and
lactate levels were performed according to the manufacturers’
instructions. The pellet was resuspended in 75ml of 10mM
Tris pH 10.4 to extract the proteins. Protein extracts were
quantified using the Bradford protein assay (Bio-Rad protein
assay reagent; Bio-Rad laboratories Ltd (UK)). The amount
of lactate and pyruvate in each sample is expressed as the
ratio of the total protein content (mg/g total protein).
Aß42 ELISA
Total Aß42 was extracted from fly heads in GnHCl buffer
(5M Guanidinium HCl, 50 mM Hepes pH 7.3, protease in-
hibitor cocktail (Sigma, P8340) and 5 mM EDTA), as previ-
ously described (Sofola O et al.). Aß42 levels were then
measured using the High Sensitivity Human Amyloid Aß42
ELISA kit (Millipore), according to the manufacturers’
instructions. Protein extracts were quantified using the
Bradford protein assay (Bio-Rad laboratories Ltd, UK) and
the amount of Aß42 in each sample expressed as a ratio of
the total protein content (pmoles/g total protein).
Fluorescence-activated cell sorting
of neurons
Green Fluorescent Protein (GFP) labelled neurons were
sorted according to DeSalvo et al.27 Briefly, 10 brains
per sample were dissected in Schneider’s medium contain-
ing 1% Bovine Serum Albumin and quickly transferred
into the same medium on ice. Samples were dissociated
as described previously and GFP positive neurons were
fluorescence-activated cell sorting (FACS) sorted straight
into lysis medium, ready for RNA extraction.
Statistical analyses
Microarray analyses are described above. For climbing assays,
data were analysed by ordinal logistic regression or linear re-
gression in R (http://www.r-project.org), using the individual
heights for each fly as data points. For lifespans, data are pre-
sented as cumulative survival curves and survival rates were
Table 1 Primers for quantitative real-time PCR analysis
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Figure 1 Overlapping transcriptional responses to early AD pathology in aged Drosophila and human brain. (A) Significant overlaps in
differentially expressed (DE) genes were observed between young (19d) and old (34d) fly brains in response to Aß42 expression (41 of 224 DE genes
analysed; p¼ 9.75e-66, Bayes moderated t-statistic and Benjamini and Hochberg FDR correction), and individual genes are detailed in Supplementary Fig.
1C. (total gene number n¼ 8566). (B) Plot depicts the number of intersecting genes that are differentially expressed in no versus early pathology in human
AD brain, across various cell types, and control versus Aß42 expression in fly brain. Red represents overlaps between human genes and alterations in
young flies and blue overlaps with old flies. Significant overlaps (P¼ 0.03; SuperExactTest) were observed only when comparing no versus early pathology
in human inhibitory neurons and control versus Aß42þ 34d (old flies). Abbreviations: In, inhibitory neurons; Ex, excitatory neurons; Ast, astrocytes; Oli,
oligodendrocytes; Opc, oligodendrocyte precursor cell; Mic, microglia. (C) Plot showing the 17 genes from the significant overlap in B (*). Genes are
upregulated in flies (red) and downregulated in humans (blue). (D) Ldh was the principal upregulated gene in response to Aß42 in aged Drosophila brain and
its human orthologue LDH was significantly downregulated in inhibitory (i) neurons (LDH A&B). LDHB expression was also downregulated in human
neurons excitatory (e), astrocytes and oligodendrocytes in brain tissue from early-stage AD patients compared with controls. The fly image in this figure
was originally created by Dr Fiona Kerr and produced in Kerr et al.56
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compared using log-rank tests in Excel. For all other experi-
ments, data are presented as means 6 SEM, from a min-
imum of 3 independent biological repeats, and were analysed
by unpaired student’s t-test or one-way ANOVA and Tukey’s
post-hoc analyses using Graphpad Prism 8.0 (https://www.
graphpad.com/scientific-software/prism/).
Data availability
The raw microarray data generated in this study are
deposited in ArrayExpress (http://www.ebi.ac.uk/arrayex
press) with identifier E-MTAB-8865.
Results
To understand how Aß toxicity is mediated in neurons, and
whether age influences this response, we measured RNA
expression in the brains of flies expressing Aß42 peptide either
early or later in life (Supplementary Fig. 1A and B). The life-
span curves associated with these induction patterns have
been published elsewhere (Fig. 2C in the study by Rogers
et al.28) 224 genes were differentially expressed between unin-
duced controls and Aß42-expressing brains at the two ages
(Supplementary Tables 1 and 2), 41 of which were in com-
mon between the young and older flies, a significant enrich-
ment (Fig. 1A, Supplementary Fig. 1C and Table 3). A larger
number of genes were altered in response to Aß42 in young
flies (Fig. 1A), possibly because young flies can activate a
more robust response, which might also explain why older
individuals are more susceptible to Aß toxicity. Most genes
with altered expression at older age were also altered in the
young brains, suggesting that the majority of these represented
generic responses to Aß42, albeit with magnitudes that varied
slightly with age (Fig. 1A, Supplementary Fig. 1C).
Figure 2 Ldh is upregulated in Aß expressing fly brains. (A) Ldh qPCR analysis of brains expressing Aß (Aßþ) and uninduced controls
(Aß). Genotypes: UAS-Aß; elav GS. (B) Ldh qPCR analysis of FACS sorted GFP expressing neurons and other cells, expressing Aß (Aß) and
driver alone (controls). Genotypes: UAS-Aß/UAS-eGFP; elav GS and UAS-eGFP; elav GS. (C and D) Ldh enzymatic assay on brain extracts
expressing Aß (Aßþ) and uninduced controls (Aß). Assayed in the direction of lactate (C) and pyruvate production (D). Values shown are
the slopes generated by the enzymatic reaction. Lactate production generates a negative slope, so a lower negative value signifies a
greater activity. Genotypes: UAS-Aß; elav GS. A, C and D were compared by t-test, B by one-way ANOVA followed by Tukey’s post-hoc test.
** P< 0.01, ****P< 0.0001, N¼ 3–5 per condition for qPCR; N¼ 7–8 per condition for LDH activity.
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A recent single-cell study also found that transcriptional
changes in Alzheimer’s disease patients early and later in
disease development were quite similar, suggesting that
there is a strong transcriptional signature early in re-
sponse to Aß42 that does not greatly change with disease
progression.8 To determine if the changes in gene expres-
sion in Drosophila brains were conserved in human
Alzheimer’s disease brains, we compared our young and
old fly data-sets to single-cell sequencing of early and late
stage Alzheimer’s disease patients versus healthy controls8
(Fig. 1B, Supplementary Table 8). Significant overlaps
were observed only between control versus Aß42 34d in
flies and no pathology versus early Alzheimer’s disease
pathology in inhibitory neurons in humans (Fig. 1B),
with 17 genes commonly regulated between Alzheimer’s
disease flies and patients (Fig. 1C). Of these, lactate de-
hydrogenase (Ldh; Drosophila ImpL3) was up-regulated
to the greatest degree in Aß42 fly brains (Fig. 1C and
D), while both LDHA and LDHB isoforms were down-
regulated in inhibitory patient neurons. LDHB was also
significantly down-regulated in excitatory neurons, astro-
cytes and oligodendrocytes of Alzheimer’s disease patients
with early pathology (Fig. 1D).
Moreover, several genes involved in the Unfolded
Protein Response (UPR) including Hsc70, CG10420 and
CaBP1 were significantly up-regulated in Aß42 fly brain,
and their orthologues HSPA5/BiP, SIL1 and PDIA6
down-regulated in inhibitory neurons of Alzheimer’s dis-
ease patients (Fig. 1C), consistent with ER-stress associ-
ated responses under Alzheimer’s disease conditions in
flies and humans. Supporting this observation, GO path-
way analyses in Drosophila (Supplementary Tables 4–7)
confirmed that UPR, ER and Golgi processes were signifi-
cantly enriched in differentially expressed upregulated
genes in both young and old Aß42 fly brain
(Supplementary Tables 4 and 6). These data suggest that
our fly model represents early stages of Alzheimer’s dis-
ease pathogenesis, but with mainly opposing effects on
expression of the same genes, including defects in LDH
and UPR levels. This discrepancy in the direction of
change requires further investigation, but may represent
cell-type specific effects which are not detectable using a
whole-brain approach to transcriptional analyses in flies
compared to human studies.
LDH catalyses the conversion of lactate into pyruvate
and vice-versa and is a key enzyme in the glycolytic cas-
cade. Its activity is increased in Alzheimer’s disease
patients’ brains,29 and mRNA levels of LDHA are higher
in fibroblasts derived from late-onset Alzheimer’s disease
patients versus controls.30 However, it is unclear whether
LDH plays a direct role in Alzheimer’s disease pathogen-
esis. Up-regulation of glycolysis in neurons, and specific-
ally of key enzymes, including LDHA, confers resistance
to Aß toxicity.31 We, therefore, sought to understand
whether the increase in LDH activity observed in flies is
itself a compensatory response to Aß42, or whether in-
stead it contributes to disease development.
We confirmed by qPCR that expression of Aß in fly
neurons leads to up-regulation of Ldh RNA in fly brains
(Fig. 2A), and this upregulation does not occur in driver
alone flies treated with RU (Supplementary Fig. 2A). This
is accompanied by increased enzymatic activity in both
directions (Fig. 2C and D). However, this increase in en-
zymatic activity did not result in an increase in either lac-
tate or pyruvate (Supplementary Fig. 2B and C). This
was, possibly, because flux through the pathway was
increased in both directions, and the steady-state metabol-
ite concentrations were hence maintained. Ldh is
Figure 3 Manipulation of Ldh leads to exacerbation of climbing defects. (A) Plot of Performance index for a negative geotaxis
assay of flies expressing Aß (Aßþ) alone compared to flies expressing Aß and Ldh (Aß Ldhþ), and their un-induced controls (Aß and Aß
Ldh). Genotypes: UAS-Aß/UAS-Ldh; elav GS, UAS-Aß; elavGS. Aß UAS Ldh was not significantly different to Aß alone (P¼ 0.139 by ordinal
logistics regression). (B) Plot of Performance index for a climbing assay of flies expressing Aß (Aßþ) alone compared to flies expressing Aß
and Ldh RNAi (Aß Ldh RNAi þ), and their un-induced controls (Aß and Aß Ldh RNAi). Genotypes: UAS-Aß/UAS-Ldh RNAi; elav GS, UAS-
Aß; elavGS. Aß Ldh RNAi genotype was significantly worse than Aß alone (P ¼ 0.00552 by ordinal logistics regression). Note experiments were
run in parallel with Aßþ and Aß curves in Fig. 3a, but depicted separately for clarity.
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expressed both in neurons and in glia, where it contrib-
utes to the neuronal lactate shuttle. In glia, Ldh catalyses
the conversion of pyruvate to lactate, which is then shut-
tled to neurons via monocarboxylate transporters where
Ldh converts it back to pyruvate which then enters gly-
colysis for rapid energy production.32 Whereas in mam-
malian systems these two reactions are catalysed by
different isoenzymes, composed of different subunits, in
flies there is a single Ldh gene (Impl3), with the same en-
zyme catalysing the reaction in both directions. We per-
formed the above enzymatic analysis of Ldh using whole
head lysates, hence further studies were required to deter-
mine whether the increase in LDH activity occurred in
neurons or in glia.
To identify which cell-types were responsible for the in-
crease in LDH activity in Alzheimer’s disease flies, we
next measured transcript levels in isolated neurons versus
non-neuronal cells in the fly. We FACS sorted GFP posi-
tive cells, using control or Aß42 flies co-expressing GFP
specifically in neurons. We confirmed that the GFP sorted
cell fractions were indeed enriched for neurons by assess-
ing the levels of the neuronal marker elav (Supplementary
Fig. 2D). We then measured Ldh mRNA levels on FACS
sorted cells, and found that Ldh increased in neurons
(Fig. 2B) but not in the other cell types in the brain.
To test whether an increase in Ldh was protective, we
generated flies over-expressing Ldh in adult neurons and
confirmed the over-expression (Supplementary Fig. 3).
We then over-expressed Ldh in adult neurons that also
expressed Aß42, and found an exacerbation of the
impaired climbing phenotype observed in these flies, sug-
gesting that Ldh up-regulation may contribute to Aß42-
induced neuronal toxicity (Fig. 3A). qPCR analysis of
Ldh transcripts showed that, even in the RU condition,
the UAS-Aß; UAS-Ldh fly lines showed increased Ldh
expression (Supplementary Fig. 3A), leading to increased
Ldh enzymatic (Supplementary Fig. 3B and C). The in-
crease in transcript and enzyme activity in the UAS line
in the un-induced condition most likely reflects the leaki-
ness of the elavGS driver.33 There was a trend towards
increased lactate levels (which did not reach significance)
and there was a slight decrease in pyruvate in the over-
expression line (Supplementary Fig. 3D and E), possibly
indicating that excessive Ldh activity in neurons is driv-
ing a higher rate of pyruvate consumption by the TCA
cycle.
To test this further, we down-regulated Ldh using
RNAi, in flies over-expressing Aß42, but this also led to
a worsening of the climbing phenotype (Fig. 3B). Again,
qPCR analysis, showed that Ldh transcripts were down-
regulated, even in the non-induced conditions, leading to
changes in enzymatic activity and metabolite levels both
in the induced and un-induced condition. This is consist-
ent with previous studies showing that RNAi lines can
display strong knock-down even in the un-induced condi-
tion.33 Pyruvate and lactate levels were very low in the
presence of Ldh RNAi, however, suggesting that Ldh
enzyme is affecting the production of both metabolites
under our experimental conditions (Supplementary Fig.
3), possibly because of a compensatory down-regulation
of the whole pathway, but this remains to be determined.
Over-expression or knock-down of Ldh, however, also
negatively affected climbing behaviour in healthy flies
(Supplementary Fig. 3F and G) suggesting that its expres-
sion must be finely-controlled to maintain metabolic
homeostasis and neuronal function. As further genetic
manipulation of Ldh also induced detrimental effects in
Aß42-expressing flies, these findings could indicate that
its natural up-regulation in response to Aß42 production
represents a compensatory mechanism to maintain opti-
mal levels of gene expression and protection against
metabolic dysfunction under these conditions.
We next investigated the potential molecular mecha-
nisms responsible for regulation of Ldh in response to
Aß42. Ldh levels are regulated by hypoxia inducible fac-
tor 1 (HIF1)34,35 in mammalian systems and by the Hif1
homologue, similar (sima), in flies.36 In Aß-resistant
human neurons, elevation of Hif1 levels is thought to
lead to increased LDHA31,37 and Hif1 protein levels are
increased in Alzheimer’s disease mouse models.31 To in-
vestigate whether sima was responsible for the up-regula-
tion of Ldh in Alzheimer’s disease fly brain in response
to Aß, we first examined the levels of sima transcript,
and observed no significant difference. However, sima
can be regulated post-transcriptionally, so this does not
rule out its involvement. We down-regulated sima genet-
ically, using a heterozygous null mutant,38 but this had
no effect on Ldh expression in brains of Aß over-express-
ing flies (Fig. 4B), suggesting that sima does not regulate
Ldh levels in response to Aß42. Down-regulation of sima
exacerbated the negative geotaxis phenotype of both Aß
and control flies, suggesting that it is generally detrimen-
tal to fly climbing but not specifically to Aß toxicity.
ATF4 is an effector of the UPR, induced downstream
of protein kinase R-like endoplasmic reticulum kinase
(PERK) and eukaryotic Initiation Factor 2 alpha
(eIF2alpha),39 and has been shown to regulate glucose
homeostasis and energy expenditure.40 In particular, in
flies it has been shown to up-regulate glycolytic enzymes,
including Ldh in response to ER stress.41 The UPR is up-
regulated in response to Aß in patients,42 animal mod-
els43 and flies.18 ATF4 is also induced in Alzheimer’s dis-
ease patient brains44 and in animal models of Alzheimer’s
disease.45 Given that both Ldh and ER-stress associated
genes were altered in response to Aß42 in our flies, we
therefore further explored potential connections between
these processes by assessing ATF4 level and its potential
functional role in mediating neuronal damage in AD.
ATF4 transcript was unaltered in Aß42 expressing flies
compared to uninduced controls (Fig. 4D). However, as
ATF4 is translationally regulated,39 alterations in mRNA
may not be expected. Indeed, down-regulation of ATF4
by RNAi dampened the increased expression of Ldh in
response to Aß42 (Fig. 4E), suggesting that ATF4 does
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contribute, at least partially, to the regulation of Ldh
under these conditions. Aß transcripts, on the other
hand, were unaltered (Supplementary Fig. 4), suggesting
the effect is specific to Ldh. ATF4 down-regulation fur-
ther decreased the climbing ability of Aß expressing flies
(Fig. 4F), providing correlative evidence to suggest that
activation of ATF4 could contribute to a protective re-
sponse to Aß42 accumulation, possibly via its up-regula-
tion of Ldh. More experiments will be required to prove
this is the case.
Discussion
We have shown that flies mount a conserved transcrip-
tional response to the accumulation of Aß42, and that
this response is similar in young and old flies. Similarly,
in humans, it was found that the ageing signature was
orthogonal to the disease response in Alzheimer’s disease
patients.8 Our findings highlight Ldh, as well as several
ER-stress associated genes, as a major transcriptional re-
sponder to early Aß42 toxicity in both young and old fly
brain. Greater transcriptional responses were detected in
response to Aß42 in the brain of young flies, but further
studies are required to confirm whether these represent
protective responses that are lost with age.
Consistent with our observation that both Ldh and
ER-associated genes are altered in both Aß fly models
and Alzheimer’s disease patient brain, we have also
shown that expression of Aß42 induces Ldh expression,
and subsequent activity, in fly brain via ATF4, a down-
stream effector of the UPR. The induction of Ldh could
Figure 4 Sima does not but ATF4 does induce Ldh. (A) qPCR for Sima in fly heads expressing Aß (Aßþ) and un-induced controls
(Aß). Genotype: UAS-Aß; elav GS. (B) qPCR of Ldh in heads from sima mutant flies expressing Aß (Aß sima J11B7þ) and their un-induced
controls (Aß, Aß sima J11B7) Genotypes: UAS-Aß; elav GS/sima J11B7, UAS-Aß; elavGS. **P< 0.01, N¼ 3–5 per condition. (C) Plot of
Performance index for a climbing assay of flies expressing Aß alone (Aßþ), together with mutant sima (Aß sima J11B7þ) as well as their
uninduced controls (Aß, Aß sima J11B7). Genotypes as above. UAS-Aß/sima J11B7 genotypes were significantly worse than Aß alone
(p¼ 4.03e-06 respectively by ordinal logistics regression) but there was no interaction with RU, suggesting the sima mutation affects control
and Aß expressing flies similarly. Note experiments were run in parallel with Aßþ and Aß curves in Fig. 3a, but depicted separately for
clarity. (D) qPCR for ATF4 in fly heads expressing Aß (Aßþ) and un-induced controls (Aß). Genotype: UAS-Aß; elav GS. (E) qPCR for Ldh in
heads from flies expressing Aß together with RNAi for ATF4. Genotypes: UAS-Aß; elavGS/UAS-ATF4 RNAi and UAS-Aß; elav GS. **P< 0.01,
N¼ 3–5 per condition. (F) Plot of Performance index for a climbing assay of flies expressing Aß alone (Aßþ), together with RNAi for ATF4
(Aß ATF4RNAi þ) and their uninduced controls (Aß and Aß ATF4RNAi). Genotypes as above. The Aß ATF4RNAi genotype displayed a
significantly worse response to RU over time relative to Aß alone (P¼ 0.03379 for a three-way interaction of RU, genotype and day by ordinal
logistics regression). Note experiments were run in parallel with Aßþ and Aß curves in Fig. 3a, but depicted separately for clarity.
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potentially be neuroprotective since both down-regulating
Ldh and blocking the Aß42-induced increase in Ldh ex-
pression using ATF4 RNAi in neurons are detrimental.
Up-regulation of Ldh has been observed in Alzheimer’s
disease patients’ brains.29 Elevated CSF Ldh activity is also
used as an indicator of neuronal damage,46 although the
exact source of this increase is not clear46 and could be
due to both cellular and blood–brain barrier damage releas-
ing the enzyme into the CSF or a direct increase in enzym-
atic activity of CSF-expressed Ldh. Our findings in the fly,
are consistent with other studies showing that up-regulation
of Ldh37 and other glycolytic enzymes31 increases resistance
to Aß toxicity in cortical neurons, however, further experi-
ments will be required to directly prove this, for example
by blocking the ATF4 induced increase in Ldh and check-
ing whether this has a detrimental effect.
We show for the first time that the Aß42 peptide dir-
ectly induces Ldh expression in an animal model.
It is interesting that the fly response appears reciprocal
to the one discovered in inhibitory human neurons.47
Inhibitory neurons are extremely susceptible to Aß tox-
icity. Severe loss of inhibitory GABAergic neurons has
also been observed in several animal models of
Alzheimer’s disease and in patients,47,48 where their de-
generation appears to precede that in other cell types, at
least in early disease stages.49 It is possible, therefore,
that fly neurons can mount a protective response to Aß,
whereas inhibitory neurons display a loss of protective
pathways, thus making them selectively susceptible to dis-
ease. Alternatively, by measuring transcriptional responses
in heterogeneous neuronal and glial cell types using a
whole-brain approach, our study may have excluded de-
tection of cell-type specific transcriptional changes in our
fly model. Hence, further work is required to investigate
these functional connections using human neuronal mod-
els of Ab toxicity.
LDH upregulation in mammalian systems has been
shown to be regulated by a variety of mechanisms,46 one
of the most prevalent being Hif1. Hif1 is responsible for
the up-regulation of glycolysis in cancer cells, leading to
the switch from oxidative to glycolytic metabolism,
through the Warburg effect, which promotes their sur-
vival.46 It has been proposed that survival of neurons in
Alzheimer’s disease can also be promoted by the
Warburg effect,37 and that this is also mediated by Hif1.
However, in our in vivo model of Aß42 toxicity the tran-
scription factor ATF4, and not sima (the fly Hif1 homo-
logue), is responsible for the induction of Ldh expression
in response to Aß42.
These findings suggest that Ldh upregulation is down-
stream of UPR activation. The UPR is mediated by 3
effectors: PERK, Iris and Atf6.50 PERK phosphorylates
eIF2alpha to inhibit canonical translation and induce the
translation of specific factors, such as ATF4. The UPR is
induced in the brain of Alzheimer’s disease patients and
in animal models,51 however, whether this is pathological
or protective is controversial.51 In particular, up-
regulation of ATF4 has been observed in Alzheimer’s dis-
ease patients’ brains,44 downstream of PERK activation
and eIF2alpha phosphorylation.44 The phosphorylation of
eIF2alpha is usually considered pathological in neurode-
generative conditions52–54 and its pharmacological or gen-
etic inhibition has been shown to protect animal models
of frontotemporal dementia55 and Alzheimer’s disease.54
Functionally, however, its role in early pathogenesis of
Alzheimer’s disease is far from clear, with studies in cells
suggesting that the up-regulation of eIF2alpha phosphor-
ylation and ATF4 activation contributes to cellular resist-
ance to Aß toxicity.44 Our in vivo data using a fly model
of Aß42 toxicity agree with this finding and further sug-
gest that ATF4 might also play a protective role, poten-
tially by contributing to Ldh induction. However,
formally demonstrating that this is indeed the case would
require deleting the binding sites for ATF4 in the Ldh en-
dogenous promoter and showing that this abrogates Ldh
induction resulting in a detrimental effect in the presence
of Aß.
This work requires further investigation, however, it
lends a word of caution towards therapies geared purely
towards down-regulating the UPR as a therapy for
Alzheimer’s disease, since part of its endogenous response
may be beneficial.
Supplementary material
Supplementary material is available at Brain Communications
online.
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